CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 22, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), a pioneering nutraceutical biotechnology company focused on the innovative field of plant-based medicines, healthy foods and sustainable packaging solutions, is pleased to announce the following news for its food and beverage division, M2Bio:

M2Bio Food and Beverage, known for its high-quality, healthy and sustainably sourced products, is taking a significant step forward with the announcement of a strategic change to its product range. After several successful years of exploring CBD-infused foods, the company has decided to discontinue this product line and focus on expanding its core offering.

This decision is based on the complex scientific and regulatory landscape surrounding CBD. Although CBD shows promise in various health applications, particularly due to its anti-inflammatory and neuroprotective effects, the challenges associated with its use in food have proven significant. Research shows that the bioavailability of CBD when ingested in food can vary widely, leading to inconsistent dosing and efficacy. In addition, the ongoing global debate and regulatory uncertainty over the classification of CBD as a food ingredient has complicated its marketability.

“We have always been committed to innovation and our foray into the CBD space was driven by a desire to explore the potential benefits of CBD in food products,” says Michael Sachar, CEO of M2Bio Food and Beverage. “However, it is equally important to recognize when the scientific, regulatory and logistical challenges outweigh the benefits. By moving away from CBD in our food products, we can streamline our operations and focus on what we do best – providing high-quality, sustainably sourced food that our customers trust and love.”

This strategic realignment is a response to the challenges that have arisen and an opportunity to further improve the company’s offering. Liviana^® The product line, known for its high-quality organic ingredients, is set to benefit from this re-orientation. Without the complications associated with CBD, M2Bio Food and Beverage anticipates broader distribution opportunities, particularly in international markets where CBD restrictions have previously posed significant obstacles.

While the company is moving away from CBD in food, its commitment to research and development in the health and wellness sector remains unwavering. M2Bio Food and Beverage will continue to explore the therapeutic potential of CBD in topical applications, particularly for pets with skin conditions. Initial studies suggest that the anti-inflammatory properties of CBD could provide relief for pets with dermatitis, a common and often chronic condition.

Jeff Robinson, CEO of M2Bio Sciences, commented on the scientific considerations behind this decision: “The bioavailability and pharmacokinetics of CBD when incorporated into food pose significant challenges. Our research shows that achieving consistent therapeutic results through ingestion is difficult due to variability in absorption and metabolism. By shifting our focus away from CBD-infused foods, we are positioning ourselves to advance in areas where we can more reliably control and optimize the health benefits of our products. This shift also opens us up to the entire global market, free from the regulatory restrictions and distribution barriers that CBD brings, and allows us to bring our products to consumers worldwide more easily and efficiently.”

M2Bio Food and Beverage is entering this new chapter with great optimism for the future. This strategic decision will open up new growth opportunities and enable the company to offer greater added value to its customers, partners and shareholders.

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp., doing business as M2Bio Sciences, is a biotechnology company focused on alternative plant-based therapies and therapeutic research in the mental health field. M2Bio’s mission is to advance plant-based medicine through the use of proven scientific and medical practices, clinical research, and emerging technologies.

M2Bio conducts research at the M2Bio Discovery Centre for AI-enabled phytomedicine research at the University of Pretoria in South Africa. The aim of the research is to provide scientific validation for the company’s growing product range, which includes innovative herbal medicines.
The company trades on the NASDAQ Over-the-Counter Bulletin Board under the trading symbol “MRES.” Publicly traded company (OTC Pink:MRES)

Contact:
Jeff Robinson, CEO
www.m2bio.co
(email protected)
+27 72 333 2148

Forward-looking statement:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements appear in several places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Real American Capital Corp., its directors or officers, including with respect to: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy.

Jeff Robinson
M2Bio Sciences Food and Beverage (Pty) Ltd
72 333 2148
Send us an email here
Visit us on social media:
on facebook.
X
LinkedIn
Instagram
YouTube
TikTok

Disclaimer:

EIN Presswire provides this news content “as is” without any warranty of any kind. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, please contact the author above.

Contact information

Jeff Robinson
Chairman and CEO: M2Bio Sciences
(email protected)
+27723332148

Related Images